EUVIMEDEUVIMED entdecken
Open Access

Impact of Treatment Response on Risk of Serious Infections in Patients With Crohn’s Disease: Secondary Analysis of the PYRAMID Registry

Dhruv Ahuja, Jiyu Luo, Yuchen Qi, Gaurav Syal, Brigid S Boland, John Chang, Christopher Ma, Vipul Jairath, Ronghui Xu, Siddharth Singh

Clinical Gastroenterology and Hepatology · 2024

DOI: 10.1016/j.cgh.2024.01.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024. Verfasst von Dhruv Ahuja und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Indira Gandhi Hospital, New Delhi, India. Hauptthemen laut MEDLINE: Crohn Disease, Adalimumab, Registries. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIDDK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Traditional risk factors for serious infections with advanced therapies in patients with Crohn's disease (CD) have been assessed at baseline before starting therapy. We evaluated the impact of treatment response on the risk of serious infections in adalimumab-treated patients with CD through secondary analysis of the PYRAMID registry (NCT00524537). METHODS: We included patients with CD who initiated adalimumab and classified them as treatment responders (achieved steroid-free clinical remission based on patient-reported outcomes) vs nonresponders (not in steroid-free clinical remission) at 6 months after treatment initiation (landmark). We compared the risk of serious infections between responders vs nonresponders between 6 and 36 months after treatment initiation through stabilized inverse probability of treatment weighting Cox proportional hazards model. RESULTS: Of 1515 adalimumab-treated patients, 763 (50.4%) were classified as responders at 6 months (37 ± 13 y; 56% female; disease duration, 9.5 ± 8.5 y). Compared with nonresponders, responders were less likely to have moderate to severe symptoms (55.6% vs 33%), or require steroids (45.5% vs 17.3%) or opiates (6.6% vs 1.3%) at baseline, without any differences in disease location, perianal disease, and prior CD complications. During follow-up evaluation, using stabilized inverse probability of treatment weighting, responders were 34% less likely to experience serious infections compared with nonresponders (hazard ratio, 0.66; 95% CI, 0.46-0.96). Risk of gastrointestinal and extraintestinal infections was lower in responders vs nonresponders. CONCLUSIONS: Patients with CD who respond to adalimumab have a lower risk of developing serious infections compared with nonresponders. These findings underscore that initiation of advanced therapy for CD may lower the risk of serious infections through effective disease control and avoidance of corticosteroids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAdalimumabRegistriesHumansMaleFemaleAdultMiddle AgedTreatment OutcomeInfectionsRisk AssessmentYoung AdultRisk FactorsAnti-Inflammatory Agents

Stichwörter der Autor:innen

BiologicsComparative EffectivenessIBDPositioningSafety

Substanzen

AdalimumabAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Medicine, Indira Gandhi Hospital, New Delhi, India.
  • Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, California.
  • Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California.
  • Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
  • Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
  • Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California; Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, C…

Förderung

  • NIDDK NIH HHS
  • NIDDK

Zitieren

APA

Ahuja, D., Luo, J., Qi, Y., Syal, G., Boland, B. S., Chang, J., Ma, C., Jairath, V., Xu, R., & Singh, S. (2024). Impact of Treatment Response on Risk of Serious Infections in Patients With Crohn’s Disease: Secondary Analysis of the PYRAMID Registry. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.01.003

Vancouver

Ahuja D, Luo J, Qi Y, Syal G, Boland BS, Chang J, et al. Impact of Treatment Response on Risk of Serious Infections in Patients With Crohn’s Disease: Secondary Analysis of the PYRAMID Registry. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2024.01.003

BibTeX
@article{Ahuja2024,
  author = {Ahuja, Dhruv and Luo, Jiyu and Qi, Yuchen and Syal, Gaurav and Boland, Brigid S and Chang, John and Ma, Christopher and Jairath, Vipul and Xu, Ronghui and Singh, Siddharth},
  title = {Impact of Treatment Response on Risk of Serious Infections in Patients With Crohn’s Disease: Secondary Analysis of the PYRAMID Registry},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1016/j.cgh.2024.01.003}
}
Kostenlos starten →